SCHEMBL6289437

SCHEMBL6289437

CCOC(=O)c1cnc2sc(Cl)cc2c1NCS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.44
CA2 P00918 1/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 3/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 6/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 4/20 0.40
ADORA1 P30542 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
P2RY12 Q9H244 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6290577 0.85 PDE4B (0.46) PDE4BKDM4EGAAMEN1KMT2A
SCHEMBL6290045 0.83 PDE4B (0.44) PDE4BCA2KDM4EGAAMEN1
SCHEMBL6293248 0.83 PDE4B (0.40) PDE4BCA2KDM4EGAAMEN1
SCHEMBL6290627 0.81 PDE4B (0.48) PDE4BCA2KDM4EGAAMEN1
SCHEMBL6289434 0.80 PDE4B (0.45) PDE4BKDM4EGAAMEN1KMT2A
SCHEMBL6290527 0.79 MAPK1 (0.42) PDE4BCA2KDM4EMEN1KMT2A
SCHEMBL6289454 0.79 CA2 (0.43) PDE4BCA2KDM4EGAAMEN1
SCHEMBL6289435 0.79 MMP1 (0.41) CA2KDM4EGAAMEN1KMT2A
SCHEMBL6290096 0.77 PDE4B (0.42) PDE4BCA2KDM4EGAAMEN1
SCHEMBL6290687 0.74 LMNA (0.56) PDE4BGAAKMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946473-B2 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors WYETH HOLDINGS CORPORATION (US) 2005-09-20 US disclosed
US-20030208066-A1 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors AMERICAN CYANAMID COMPANY 2003-11-06 US disclosed
EP-1279674-A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors American Cyanamid Company (US) 2003-01-29 EP disclosed
EP-1157024-B1 ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS AMERICAN CYANAMID CO (US) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208066-A1 Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors SI, TNF, PTDSS1 PDE4B 3874/4885CA2 2024/4885KDM4E 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.